New diagnostic definition of myocardial infarction issued

New diagnostic definition of myocardial infarction issued
An updated universal definition of myocardial infarction includes detection of a rise and/or fall in cardiac biomarker values, preferably cardiac troponin, according to a statement published online Aug. 26 in Circulation to coincide with presentation at the annual European Society of Cardiology Congress, held from Aug. 25 to 29 in Munich.

(HealthDay)—An updated universal definition of myocardial infarction (MI) includes detection of a rise and/or fall in cardiac biomarker values, preferably cardiac troponin (cTn), according to a statement published online Aug. 26 in Circulation to coincide with presentation at the annual European Society of Cardiology Congress, held from Aug. 25 to 29 in Munich.

Kristian Thygesen, Ph.D., from the Aarhus University Hospital in Denmark, and colleagues on the Joint /American College of Cardiology Foundation//World Heart Federation Task Force for the Universal Definition of created the revised definition to be used to better diagnose patients and define clinical trial end points.

The Joint Task Force defined an acute MI as evidence of consistent with acute myocardial ischemia. In this case, the criteria for MI are met with detection of a rise and/or fall of cardiac biomarker values, ideally cTn, with one or more value above the 99th percentile upper reference limit, in conjunction with at least one of the following: symptoms of ischemia; new or presumed new significant ST-segment-T wave changes or new left bundle branch block; development of pathologic Q waves; imaging evidence of new loss of myocardium or abnormality of regional wall motion; or identification of an intracoronary thrombus. In addition, specific criteria are provided for percutaneous coronary intervention-, stent thrombosis-, and grafting-related MIs.

"This is a truly global document that will be used worldwide," Thygesen said in a statement. "It will help doctors diagnose their patients so that they can provide the most appropriate treatment, and help researchers design clinical trials with standardized end points."

Several Task Force members and additional contributors disclosed financial ties to the pharmaceutical and biomedical industries.

More information: Full Text
More Information

add to favorites email to friend print save as pdf

Related Stories

QRS width on ECG linked to sudden cardiac arrest in CAD

Apr 20, 2012

(HealthDay) -- For patients with coronary artery disease (CAD), QRS width on electrocardiogram and echocardiographic evidence of heart failure are associated with out-of-hospital sudden cardiac arrest (SCA), ...

Recommended for you

Cerebrovascular reserve-based strategy is cost-effective

13 hours ago

(HealthDay)—A decision rule based on assessment of cerebrovascular reserve (CVR) seems to be cost-effective for prevention of stroke in asymptomatic patients with carotid artery stenosis, according to a ...

New hypertension guidelines could save lives and money

Jan 28, 2015

Full implementation of new hypertension guidelines could prevent 56,000 cardiovascular disease events (mostly heart attacks and strokes) and 13,000 deaths each year, without increasing overall health care costs, an analysis ...

Manchester United's rising stars revolutionize heart health

Jan 28, 2015

A unique research project to identify the effects of exercise on young hearts has been announced today [Wednesday 28 January 2015]. Manchester United's Academy players are being put through their paces having their hearts ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.